The safety of phosphate binders

Expert Opinion on Drug Safety

Volumn 5, Issue 5, 2006, Pages 675-686

  Daly, Jaume Almirall ^a   Valenzuela Mujica, Maria Pau ^b  

^a PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

^b NONE

Author keywords

Aluminium hydroxide; Calcium salt; End stage renal disease; Hyperphosphataemia; Lanthanum; Phosphate binder; Sevelamer

Indexed keywords

ALUMINUM HYDROXIDE; BICARBONATE; CALCIMIMETIC AGENT; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; CITRATE CALCIUM; FERRIC HYDROXIDE; IRON POLYMALTOSE; IRON SALT; LANTHANUM CARBONATE; MAGNESIUM; MAGNESIUM CARBONATE; NICOTINIC ACID; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; SEVELAMER; VITAMIN D; PHOSPHATE BINDING PROTEIN; POLYAMINE;

ABDOMINAL PAIN; ANOREXIA; BLOATING; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DIARRHEA; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; EPIGASTRIC PAIN; GLOMERULUS FILTRATION RATE; HALLUCINATION; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERMAGNESEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY CALCIFICATION; MEDICAL DECISION MAKING; METABOLIC ACIDOSIS; MICROCYTIC ANEMIA; MINERAL METABOLISM; MORTALITY; NAUSEA AND VOMITING; NONHUMAN; OSTEOMALACIA; PALATABILITY; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PRESCRIPTION; PROTEIN INTAKE; RAT; RENAL OSTEODYSTROPHY; REVIEW; SECONDARY HYPERPARATHYROIDISM; SEIZURE; THROMBOCYTOPENIA; BLOOD; DISORDERS OF MINERAL, ELECTROLYTE AND METAL METABOLISM; EXPERT WITNESS; METABOLISM; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY;

CARDIOVASCULAR DISEASES; EXPERT TESTIMONY; HUMANS; KIDNEY FAILURE, CHRONIC; PHOSPHATE-BINDING PROTEINS; PHOSPHORUS METABOLISM DISORDERS; POLYAMINES; RENAL DIALYSIS;

EID: 33747462128     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.5.675     Document Type: Review

References (92)

1. LIU S, TANG W, ZHOU J et al.: Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. (2006) 17:1305-1315.
2. LOPEZ-HILKER S, DUSSO A, RAPP N, MARTIN KJ, SLATOPOLSKY E: Phosphorous restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am. J. Physiol. (1990) 259:432-437.
3. SLATOPOLSYK E, DELMEZ JA: Pathogenesis of secondary hyperparathyroidism. Am. J. Kidney Dis. (1994) 23:229-236.
4. QUNIBI WY: Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD). Kidney Int. Suppl. (2004) 90:S8-S12.
5. BLOCK GA, PORT FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am. J. Kidney Dis. (2000) 35:1226-1237.
6. GUÉRIN AP, LONDON GM, MARCHAIS SJ, METIVIER F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol. Dial. Transplant. (2000) 15:1014-1021.
7. GOODMAN WG, GOLDIN J, KUIZON BD et al.: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. (2000) 342:1478-1483.
8. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am. J. Kidney Dis. (1998) 31:607-617.
9. GANESH SK, STACK AG, LEVIN NW, HULBERT-SHEARON T, PORT FK: Association of elevated serum P, Ca × P product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. (2001) 12:2131-2138.
10. BLOCK GA, KLASSEN PS, LAZARUS JM, OFSTHUN N, LOWRIE EG, CHERTOW GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. (2004) 15:2208-2218.
11. US RENAL DATA SYSTEM: USRDS 2002 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, USA (2002).
12. HEWITT CD, SAVORY J, WILLS MR: Aspects of aluminum toxicity. Clin. Lab. Med. (1990) 10:403-422.
13. MONIER-FAUGERE MC, MALLUCHE HH: Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients. Nephrol. Dial. Transplant. (1996) 11(Suppl. 3):S111-S120.
14. MALLUCHE HH, MONIER-FAUGERE MC: Hyperphosphatemia: pharmacologic intervention yesterday, today and tomorrow. Clin. Nephrol. (2000) 54:309-317.
15. SHERRARD DJ, HERCZ G, PEI Y et al.: The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int. (1993) 43:436-442.
16. MUNTNER P, HE J, HAMM L, LORIA C, WHELTON PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J. Am. Soc. Nephrol. (2002) 13:745-753.
17. FOLEY RN, PARFREY PS, SARNAK MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. (1998) 32:S112-S119.
18. HSU CH: Are we mismanaging calcium and phosphate metabolism in renal failure? Am. J. Kidney Dis. (1997) 29:641-649.
19. KESTENBAUM B, SAMPSON JN, RUDSER KD et al.: Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. (2005) 16:520-528.
20. TONELLI M, SACKS F, PFEFFER M, GAO Z, CURHAN G: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation (2005) 112:2627-2633.
21. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. (2003) 42(Suppl. 3):S1-S201.
22. ACHINGER SG, AYUS JC: The role of daily dialysis in the control of hyperphosphatemia. Kidney Int. Suppl. (2005) 95:S28-S32.
23. SALUSKY IB, FOLEY J, NELSON P et al.: Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N. Engl. J. Med. (1991) 324:527-531.
24. ALFREY AC, LEGENDRE GR, KAEHNY WD: The dialysis encephalopathy syndrome. Possible aluminium intoxication. N. Engl. J. Med. (1976) 294:184-188.
25. GOODMAN WG: Bone disease and aluminum: pathogenic considerations. Am. J. Kidney Dis. (1985) 6:330-335.
26. LORENZO V, MARTIN-MALO A, PEREZ-GARCIA R et al.: Prevalence, clinical correlates and therapy cost of mineral abnormalities among heamodialysis patients: a cross-sectional multicentre study. Nephol Dial Transplant (2006) 21:459-465.
27. RITZ E: Managing mineral balance in end-stage renal disease. Nephrol. Dial. Transplant. (2004) 19(Suppl. 1):S1-S3.
28. GUILLOT AP, HOOD VL, RUNGE CF, GENNARI FJ: The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron (1982) 30:114-117.
29. OE PL, LIPS P, VAN DER MEULEN J et al.: Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis. Clin. Nephrol. (1987) 28:180-185.
30. O'DONOVAN R, BALDWIN D, HAMMER M, MONIZ C, PARSONS V: Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet (1986) 1:880-882.
31. DELMEZ JA, KELBER J, NORWORD KY, GILES KS, SLATOPOLSKY E: Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int. (1996) 49:163-167.
32. MORINIERE P, VINATIER I, WESTEEL PF et al.: Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralisation. Nephrol. Dial. Transplant. (1988) 3:651-656.
33. CUSHNER HM, COPLEY JB, LINDBERG JS, FOULKS CJ: Calcium citrate, a non aluminium containing phosphate-binding agent for treatment of CRF. Kidney Int. (1988) 33:95-99.
34. MAKOFF DL, GORDON A, FRANKLIN SS, GERSTEIN AR, MAXWELL MH: Chronic calcium carbonate therapy in uremia. Arch. Intern. Med. (1969) 123:15-21.
35. SLATOPOLSKY E, WEERTS C, LOPEZ-HILKER S et al.: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N. Engl. J. Med. (1986) 315:157-161.
36. INDRIDASON OS, QUARLES LD; for the Durham Renal Osteodystrophy Study Group: Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int. (2000) 57:282-292.
37. ALMIRALL J, CAMPISTOL JM, TORRAS A, LOPEZ-PEDRET J, REVERT L: Efficacy of calcium carbonate as phosphorus-chelating agent in hemodialysis patients. Med. Clin. (Barc) (1998) 11:409-412
38. SLATOPOLSKY E, WEERTS C, NORWOOD K et al.: Long term effects of calcium carbonate and 2.5 mEq/L calcium dialysate on mineral metabolism. Kidney Int. (1989) 36:897-903.
39. SHEIKH MS, MAGUIRE JA, EMMETT M et al.: Reduction of dietary phosphorus absorption by phosphorus binders: a theoretical in vitro and in vivo study. J. Clin. Invest. (1989) 83:66-73.
40. MAI ML, EMMETT M, SHEIKH MS, SANTA ANA CA, SCHILLER L, FORDTRAN JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. (1989) 36:690-695.
41. EMMETT M, SIRMON MD, KIRKPATRICK WG, NOLAN CR, SCHMITT GW, CLEVELAND MB: Calcium acetate control of serum phosphorus in hemodialysis patients. Am. J. Kidney Dis. (1991) 17:544-550.
42. SCHAEFER K, SCHEER J, ASMUS G, UMLAUF E, HAGEMANN J, VON HERRATH D: The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: A comparative study. Nephrol. Dial. Transplant. (1991) 6:170-175.
43. PFLANZ S, HENDERSON IS, MCELDUFF N, JONES MC: Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic hemodialysis. Nephrol. Dial. Transplant. (1994) 9:1121-1124.
44. RING T, NIELSEN C, ANDERSEN SP, BEHRENS JK, SODEMANN B, KORNERUP HJ: Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic hemodialysis: a controlled study. Nephrol. Dial. Transplant. (1993) 8:341-346
45. MORINIERE PH, DJERAD M, BOUDAILLIEZ B et al.: Control of predialytic hyperphosphatemia by oral calcium Acetate and Calcium Carbonate. Nephron (1992) 60:6-11.
46. CARAVACA F, SANTOS I, CUBERO JJ et al.: Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis Patients. Nephron (1992) 60:423-427.
47. ALMIRALL J, VECIANA L, LLIBRE J: Calcium acetate versus Calcium carbonate for the control of serum phosphorus in haemodialysis patients. Am. J. Nephrol. (1994) 14:192-196.
48. BEN HAMIDA F, EL ESPER I, COMPAGNON M, MORINIERE P, FOURNIER A: Long term (6 month) cross-over comparison of calcium acetate with calcium carbonate as phosphate-binder. Nephron (1993) 63:258-262
49. FOURNIER A, MORINIERE P, SEBERT JL et al.: Calcium carbonate, an aluminium-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia. Kidney Int. (1986) 18:S114-S119.
50. COLADONATO JA, SZCZECH LA, FRIEDMAN EA, OWEN WF Jr: Does calcium kill ESRD patients? The skeptic's perspective. Nephrol. Dial. Transplant. (2002) 17:229-232.
51. SHARPLES EJ, PEREIRA D, SUMMERS S et al.: Coronary artery calcification measured with electron-beam computerized tomography correlates poorly with coronary artery angiography in dialysis patients. Am. J. Kidney Dis. (2004) 43:313-319.
52. HUANG H, VIRMANI R, YOUNIS H, BURKE AP, KAMM RD, LEE RT: The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation (2001) 103:1051-1056.
53. CHERTOW GM, BURKE SK, LAZARUS JM et al.: Poly[allylamine hydrochloride] (Renagel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am. J. Kidney Dis. (1997) 29:66-71.
54. SLATOPOLSKY EA, BURKE SK, DILLON MA; the RenaGel Study Group: RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int. (1999) 55:299-307.
55. WILKES BM, REINER D, KERN M, BURKE S: Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin. Nephrol. (1998) 50:381-386.
56. BLEYER AJ, BURKE SK, DILLON M et al.: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am. J. Kidney Dis. (1999) 33:694-701.
57. CHERTOW GM, DILLON M, BURKE SK et al.: A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin. Nephrol. (1999) 51:18-26.
58. CHERTOW GM, BURKE SK, RAGGI P; for the treat to goal working group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. (2002) 62:245-252.
59. ALMIRALL J, LOPEZ T, VALLVE M, RUIZ A, LLIBRE J, BETRIU A: Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of hemodialysis patients. Nephron Clin. Prac. (2004) 97:c17-c22.
60. BURKE SK, SLATOPOLSKY EA, GOLDBERG DI: RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol. Dial. Transplant. (1997) 12:1640-1644.
61. GOLDBERG DI, DILLON MA, SLATOPOLSKY EA et al.: Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol. Dial. Transplant. (1998) 13:2303-2310.
62. SADEK T, MAZOUZ H, BAHLOUL H et al.: Sevelamer hydrochloride with or without alpha calcidol or higher dialysate calcium versus calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol. Dial. Transplant. (2003) 18:582-588
63. BORRAS M, MARCO MP, FERNANDEZ E: Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients. Perit. Dial. Int. (2002) 22:737-738.
64. GALLIENI M, COZZOLINO M, BRANCACCIO D: Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder. Kidney Int. (2000) 57:1776-1777.
65. BREZINA B, QUNIBI WY, NOLAN CR: Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int. (2004) 90:S39-S45.
66. MCCULLOUGH PA, SANDBERG KR, DUMLER F, YANEZ JE: Determinants of coronary vascular calcification in patients with chronic kidney disease and end stage renal disease: a systematic review. J. Nephrol. (2004) 17:205-215.
67. VAUGHAN CJ, GOTTO AM JR, BASSON CT: The evolving role of statins in the management of atherosclerosis. J. Am. Coll. Cardiol. (2000) 35:1-10.
68. QUNIBI WY: Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). Kidney Int. (2005) 95:S43-S50.
69. QUNIBI WY, HOOTKINS RE, MCDOWELL LL et al.: Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. (2004) 65:1914-1926.
70. MANNS B, STEVENS L, MISKULIN D, OWEN WF Jr, WINKELMAYER WC, TONELLI M: A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int. (2004) 66:1239-1247.
71. LOCATELLI F, D'AMICO M, PONTORIERO G: Lanthanum carbonate. Drugs (2003) 6:688-695.
72. JOY MS, FINN WF: Randomized, double-blind, placebocontrolled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am. J. Kidney Dis. (2003) 42:96-107.
73. HUTCHISON AJ, SPEAKE M, AL-BAAJ F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol. Dial. Transplant. (2004) 19:1902-1906.
74. FINN WF, JOY MS, HLADIK G; the Lanthanum Study Group: Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin. Nephrol. (2004) 62:193-201.
75. LACOUR B, LUCAS A, AUCHERE D, RUELLAN N, DE SERRE PATEY NM, DRUEKE TB: Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. (2005) 67:1062-1069.
76. BEHETS GJ, VERBERCKMOES SC, OSTE L et al.l: Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int. (2005) 67:1830-1836.
77. D'HAESE PC, SPASOVSKI GB, SIKOLE A et al.: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. (2003) 85(Suppl.):S73-S78.
78. FREEMONT AJ, HOYLAND JA, DENTON J; Lanthanum Carbonate SPD405-303 Study Group: The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin. Nephrol. (2005) 64:428-437.
79. HUTCHISON AJ, MAES B, VANWALLEGHEM J et al.: Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin. Pract. (2006) 102:c61-c71.
80. HERGESELL O, RITZ E: Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol. Dial. Transplant. (1999) 14:863-867
81. HSU CH, PATEL SR, YOUNG EW: New phosphate binding agents: ferric compounds. J. Am. Soc. Nephrol. (1999) 10:1274-1280.
82. ETO N, MIYATA Y, OHNO H, YAMASHITA T: Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol. Dial. Transplant. (2005) 20:1378-1384.
83. TAKAHASHI Y, TANAKA A, NAKAMURA T et al.: Nicotinamide supresses hyperphosphatemia in hemodialysis patients. Kidney Int. (2004) 65:1099-1104.
84. SAMPATHKUMAR K, SOORAJ YS, AJESHKUMAR RP: Extended release nicotinic acid is a promising agent for phosphate control in hemodialysis. Kidney Int. (2006) 69:1281
85. GOODMAN WG, HLADIK GA, TURNER SA et al.: The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J. Am. Soc. Nephrol. (2002) 13:1124-1125
86. SZCZECH LA: The impact of calcimimetic agents on the use of different classes of phosphate binders: Results of recent clinical trials. Kidney Int. (2004) 66:S46-S48.
87. SHAHAPUNI I, MANSOUR J, HARBOUCHE L et al.: How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Semin. Dial. (2005) 18:226-238.
88. BLOCK GA, MARIN KJ, DEFRANCISCO ALM et al.: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. (2004) 350:1516-1525.
89. QUARLES LD, SHERRARD DJ, ADLER S et al.: The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J. Am. Soc. Nephrol. (2003) 14:575-583.
90. LINDBERG JS, MOE SM, GOODMAN WG et al.: The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism. Kidney Int. (2003) 63:248-254.
91. YOUNG EW, AKIBA T, ALBERT JM et al.: Magnitude and impact of abnormal mineral metabolism in hemodialysis in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. (2004) 5(Suppl. 2):34-38.
92. WOLCOTT DL, MAIDA CA, DIAMOND R, NISSENSON AR: Treatment compliance in end-stage renal disease patients on dialysis. Am. J. Nephrol. (1986) 6:329-338.